GSK receives a positive CHMP opinion for intravenous zanamivir for the treatment of complicated influenza
Issued: London, UK
GSK today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for intravenous zanamivir for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥6 months) when the patient’s influenza virus is known or suspected to be resistant to anti-influenza agents other than zanamivir, and/or other anti-viral agents for treatment of influenza, including inhaled zanamivir (Relenza), are not suitable for the individual patient.
The marketing authorisation application was submitted under the exceptional circumstances regulatory legislation in the European Union. A CHMP positive opinion is one of the final steps before marketing authorisation is granted by the European Commission. When approved, the intravenous formulation of zanamivir will be known as Dectova.
GSK - a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us
Find out more about us
Image and video library
Images can be downloaded in low and high resolution. Our YouTube channel offers a regularly updated collection of GSK videos